Amsterdam, 22 - 24 March 2022

Schedule

Create your personal agenda –check the favourite icon

Mar 2208:55
Conference pass

Chair’s remarks

Keynotes
Claus Runge, Global Head of Market Access, Public Affairs & Sustainability, Bayer
Mar 2209:00
Conference pass

Transforming healthcare delivery with data and evidence

Keynotes
Michael Seewald, VP, Global Evidence, Medical BioPharmaceuticals, AstraZeneca
Mar 2209:40
Conference pass

Keynote Panel Discussion: Navigating the Market Access, RWE and Pricing Landscape in a Pandemic: Overcoming challenges, embracing opportunities and looking to the future

Keynotes
Claus Runge, Global Head of Market Access, Public Affairs & Sustainability, Bayer
Suzanne Mcgurn, President and CEO, CADTH
Claudia Neuber, Head of Global Pricing, AstraZeneca
Carla Deakin, Programme Director - Commercial And Managed Access, NICE
Christoph Glatzer, Head of Global Market Access, Pricing, RWE, PRO, Johnson & Johnson
Saira Jan, Vice-President & Chief Pharmacy Officer, Blue Cross Blue Shield of New Jersey
Mar 2211:20
Conference pass

Chair’s remarks

Evidence: RWE
Sanjay Gupta, Vice President, Head of Global RWE & US HEOR, Eisai
Mar 2211:20
Conference pass

Chair’s remarks

Market Access & Pricing: Value-based Contracting
Navin Joshi, Head of Pricing & Market Access, GlaxoSmithKline
Mar 2211:20
Conference pass

Chair’s remarks

Rare Diseases: Patient Access To Rare Disease Treatments
Scott Williams, Head, Global Public Affairs Rare Diseases and Rare Blood Disorders, Sanofi Genzyme
Mar 2211:20
Conference pass

Chair’s remarks

Big Data, AI & Digital: Data Analytics And AI
Francesca Tavella, Global payer analytics lead, AstraZeneca
Mar 2211:25
Conference pass

Growing opportunities for RWE in the German HTA framework

Evidence: RWE
Tanja Heidbrede, Head RWE Central EU, UCB
Mar 2211:25
Conference pass

Industry perspective on value-based contracting

Market Access & Pricing: Value-based Contracting
Ad Antonisse, Director Market Access & External Affairs, AstraZeneca BV
Mar 2211:25
Conference pass

Understanding the challenges of uncertainties for patient access to rare disease treatments in Quebec

Rare Diseases: Patient Access To Rare Disease Treatments
Luc Boileau, Chief Executive Officer, INESSS
Mar 2211:25
Conference pass

Latest developments in data analytics for healthcare in Russia

Big Data, AI & Digital: Data Analytics And AI
Vladimir Mladov, HTA Manager, BIOCAD
Mar 2212:05
Conference pass

The impact of COVID-19 on RWE: What does the future hold?

Evidence: RWE
Sreeram Ramagopalan, Global Head Real-World Evidence (Market Access), Roche
Mar 2212:05
Conference pass

Insights from a payer for value-based contracts

Market Access & Pricing: Value-based Contracting
Kärt Veliste, Chief Specialist at Department of Medicines and Medical Devices, Haigekassa Estonia
Mar 2212:05
Conference pass

Learnings from Switzerland: Improving patient access to rare disease treatments

Rare Diseases: Patient Access To Rare Disease Treatments
Andreas Uttenweiler, Head Patient Value Access & Public Affairs, Takeda Pharma AG
Mar 2212:05
Conference pass

How AI & Machine Learning can improve patient access to orphan drugs

Big Data, AI & Digital: Data Analytics And AI
Vidya Breeveld, Head Public affairs & Market Access, Sanofi
Mar 2213:55
Conference pass

Roundtables

Keynotes
Roundtable 10: Facilitating more efficient negotiations for innovative therapies: Value-based negotiation framework
Hassan Bruneo, Head of Market Access, Pricing & Policy, Canada/Europe/MEA, Alnylam Pharmaceuticals
Julien Patris, Director Market Access & Policy – Europe / Canada / MEA (CEMEA), Alnylam
Roundtable 11: Formulating and navigating the market access & reimbursement components for a first global launch: The next big step for a start-up
Keith White, Head, Global Market Access, Amylyx Pharmaceuticals
Roundtable 12: Bringing start-ups and health-care companies together to create innovation and value for patients
Nico Bacharidis, Founder, growpal
Roundtable 13: HTA & Reimbursement considerations in the Balkan countries
Dragana Atanasijevic, Head of HTA Department, Institute of Public Health of Serbia
Roundtable 14: Exploring patient access and pricing for ultra-rare diseases
Kevin Rieger, Head Of Public And Governmental Affairs Dach, Ipsen Pharma Gmbh
Roundtable 15: Developing a strong partnership with external customers (patients, physicians, payers): What can pharma do better?
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Medical Advisor, CZ
Gustavo Saraiva Dos Anjos, Global Payer Strategy Director, Biologics, GlaxoSmithKline
Roundtable 16: Key developments in market access and pricing for China
Sylvie Greneche, Global Head of Market Access, General Medicines, Sanofi
Roundtable 17: Considerations in market access and pricing for medium-sized pharma/biotech companies
GAEL LE ROUZO, Global Market Access Director, Eusa Pharma
Roundtable 18: Market access and pricing developments in Benelux
Inneke Van De Vijver, Strategic Advisor - Reimbursement Pharmaceuticals, R.I.Z.I.V. I.N.A.M.I. National Health Insurance Agency
Bart Van Den Daele, Head of External Affairs – Director Market Access - Belux, Gilead Sciences
Wim Goettsch, Special Hta-Advisor, Zorginstituut
Roundtable 19: HTA and conditional reimbursement in the Nordics
Line Brøns, Senior health economist, Amgros I/S
Leung-Ming Yu, Senior Advisor, HTA and reimbursement, Norwegian Medicines Agency
Roundtable 1: Pricing and reimbursement for the EU 5 and UK
Fabrizio Zucca, Director Market Access DACH, Alnylam Pharmaceuticals
Roundtable 20: The evolving drug policy landscape in Canada: PMPRB reforms, pharmacare, orphan drugs and the creation of the CDA
Trevor Richter, Director Access and Reimbursement, Canada, Gilead Sciences
Roundtable 21: Achieving market authorisation based on single arm studies compared RWE: Are HTA bodies willing to accept the same data?
Jörg Tomeczkowski, Associate Director, Global HTA Decision Support, Janssen
Roundtable 22: US payer evaluation of patient-centric trials: what does this mean for US payers?
Ed Pezalla, Former Vice President, National Medical Director For Pharmaceutical Policy And Strategy, Aetna; a CVS Pharmacy Health Company
Roundtable 23: Pricing and access of new multiple sclerosis therapies in an increasingly competitive landscape
Nicki Catterick, VP, Head of Global Market Access & Pricing | Neurology & Immunology, Merck Group
Roundtable 24: A patient-centric approach to value in gene therapies
Nanxin (Nick) Li, Global/US Market Access Lead, uniQure
Roundtable 2: Utilising RWE effectively to support new therapies
Daria Tolkacheva, Head of Health Technology Assessment, JSC BIOCAD
Roundtable 3: Exploring valued-based healthcare and patient outcomes: Leveraging shared decision-making
Marnix Artz, Head of Patient Access, Pricing & Public Affairs, Netherlands, Merck Group
Roundtable 4: Challenges arising from post-pandemic budget constraints in European healthcare systems: What can industry expect?
Michael Muller, Head Of Market Access, Western Europe, Sun Pharma
Roundtable 5: Smart procurement practices for biosimilars
Diogo Piedade, Market Access Manager, Medicines for Europe
Roundtable 6: Returning to the new normal: HTA & Reimbursement challenges in a post-pandemic world
Glenn Anley, Global Director Pricing & Access - Covid Therapeutics, GSK
Roundtable 7: Unlocking the potential of analytics and digital to improve patient outcomes
Francesca Tavella, Global payer analytics lead, AstraZeneca
Roundtable 8: Why Anti-Microbial Resistance is a global concern: How do we enable anti-microbial developers to deliver new therapies in a sustainable manner?
Sara Lopes, Senior Director, Global Market Access & Pricing Governance, Shionogi BV
Warren Cowell, Director Market Access UK, Shionogi Ltd
Steve Sandor, Vice President, Market Access And Trade, Paratek Pharmaceuticals , Inc.
Roundtable 9: Developing partnerships with healthcare disruptors: Implications for market access and the wider healthcare ecosystem
Adam Kundzewicz, Global Head of Tech Partnerships, Boehringer Ingelheim
Mar 2214:50
Conference pass

Chair’s remarks

Evidence: RWE
Ana Filipa Alexandre, Global Director, Health Economics Outcomes Research, Astellas Pharma
Mar 2214:50
Conference pass

Chair’s remarks

Market Access & Pricing: Working With Payers
Sandro Cesaro-Tadic, Head Strategic Product Pricing, Roche
Mar 2214:50
Conference pass

Chair’s remarks

Rare Diseases: Patient Access To Rare Disease Treatments
Giovanni Tafuri, Director, International Pricing & Reimbursement and Policy Strategy, Apellis Pharmaceuticals
Mar 2214:50
Conference pass

Chair’s remarks

Big Data, AI & Digital: Data Analytics And AI
Teddy Sun, Senior Manager, Value Strategy & Payer Engagement, Novo Nordisk
Mar 2214:55
Conference pass

Future trends and optimizing RWD to improve public health

Evidence: RWE
Shrividya Iyer, Executive Director, Global RWE & US HEOR, Eisai
Mar 2214:55
Conference pass

The evolving US payer landscape

Market Access & Pricing: Working With Payers
Robert Orzechowski, Chief Operating Officer, Lancaster Cancer Centre
Mar 2214:55
Conference pass

Considerations for the approval of orphan drugs at a national level: The patient perspective

Rare Diseases: Patient Access To Rare Disease Treatments
Ines Alves, President, ANDO Portugal
Mar 2214:55
Conference pass

Using RWE analytics to inform strategic decision-making

Big Data, AI & Digital: Data Analytics And AI
Yonghua Jing, Director, Real World Evidence & Analytics, Health Economics & Outcomes Research, AbbVie
Mar 2215:15
Conference pass

Payer Perspectives on Value Assessment, navigating the global landscape

Market Access & Pricing: Working With Payers
Ramiro Gilardino, Head, Value & Access Communications, Healthcare Consultancy Group
Mar 2215:35
Conference pass

Realising the contribution of RWE in your evidence package when making regulatory submissions

Evidence: RWE
Ramon Hernandez Vecino, Global Head of Development Real World Evidence, Sanofi
Mar 2215:35
Conference pass

Latest developments on the Dutch drug access protocol

Market Access & Pricing: Working With Payers
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Medical Advisor, CZ
Mar 2215:35
Conference pass

The impact of the Biden administration on access to rare disease treatments

Rare Diseases: Patient Access To Rare Disease Treatments
Erin Mistry, SVP, Head of Payer Strategy, Gov’t Affairs and Trade Relations, CorMedix Inc
Mar 2215:35
Conference pass

Who is better? AI bot or human clinician

Big Data, AI & Digital: Data Analytics And AI
Chris Wasden, Head of HappifyDTx, HAPPIFY HEALTH
Mar 2216:25
Conference pass

Chair’s remarks

Evidence: RWE
Enkeleida Nikai, Head Of Real World Evidence, Senior Director At Janssen Europe, Middle East And Africa (Emea), Janssen Pharmaceutical
Mar 2216:25
Conference pass

Chair’s remarks

Market Access & Pricing: Value
Marco Rauland, Vice President Global Market Access & Pricing - Strategic Planning, Merck Group
Mar 2216:25
Conference pass

Chair’s remarks

Rare Diseases: Regulatory Landscape of Orphan Drugs
Jolanda Koenders, Head Of Patient Value And Access, Takeda
Mar 2216:25
Conference pass

Chair’s remarks

Big Data, AI & Digital: Digital Health
Shrividya Iyer, Executive Director, Global RWE & US HEOR, Eisai
Mar 2216:30
Conference pass

RWE generation for HTA reimbursement of digital interventions

Evidence: RWE
Bogdan Muresan, Associate Director Global HEOR, Teva Pharmaceutical Europe
Mar 2216:30
Conference pass

Demonstrating value for rare disease treatments

Market Access & Pricing: Value
Marco Penske, Head Of Market Access And Health Care Affairs, Boehringer-Ingelheim
Mar 2216:30
Conference pass

A new perspective on access to OMPs for ultra-rare diseases

Rare Diseases: Regulatory Landscape of Orphan Drugs
Philippe Ghyssels, VP, Corporate and Global Public Affairs, Ipsen
Mar 2216:30
Conference pass

How private payers make use of digital tools to improve patient health and contain treatment costs?

Big Data, AI & Digital: Digital Health
Charles-Etienne de Cidrac, Director Of Health Insurance, AXA
Mar 2217:10
Conference pass

How RWD can be used to create a more equitable healthcare ecosystem

Evidence: RWE
Ulrike Jacobi, Head Of External Affairs And Market Access, Amgen
Mar 2217:10
Conference pass

Learnings from Canada: Regulatory price review of high-cost medicines

Rare Diseases: Regulatory Landscape of Orphan Drugs
Elena Lungu, Manager of Policy Development, Patented Medicine Prices Review Board, Government of Canada
Mar 2217:10
Conference pass

Developing a pricing & reimbursement framework that integrates digital health and pharmaceuticals

Big Data, AI & Digital: Digital Health
Jesper Bjerggren, European Market Access Lead Respiratory/Digital Health, Teva Pharmaceuticals

Create your personal agenda –check the favourite icon

Mar 2308:55
Conference pass

Chair’s remarks

Keynotes
Wills Hughes-Wilson, Chief Patient Access & Commercial Planning, Mereo Biopharma
Mar 2309:00
Conference pass

Exploring the pricing and market access dynamics for rare diseases: Where is the world going?

Keynotes
Pernille Storm, Head of Global Pricing, H. Lundbeck A/S
Mar 2309:40
Conference pass

The commercial landscape for NHS England: Considerations for success and engagement

Keynotes
Tamir Singer, Head of Commercial Development, NHS England
Mar 2311:20
Conference pass

Chair’s remarks

Evidence: Capability-building
Alex Bastian, Vice President, Value And Market Access, Galapagos NV
Mar 2311:20
Conference pass

Chair’s remarks

Market Access & Pricing: Medical Devices & Diagnostics
Andrea Rappagliosi, Vice President Market Access, Public Affairs & Communication EMEA, Canada and LATAM, Edwards Lifesciences
Mar 2311:20
Conference pass

Chair’s remarks

Rare Diseases: Sustainability Of Orphan Drugs
Laurene Redding, Head, Value, Access & Policy, Canada, BeiGene
Mar 2311:20
Conference pass

Chair’s remarks

Advanced Therapies: Risk-sharing, Access and Reimbursement
Francesca Cook, Vice President, Pricing and Marketing Access, RegenxBio
Mar 2311:25
Conference pass

Ensuring co-creation of an appropriate evidence base to deliver reimbursable medicines

Evidence: Capability-building
Daniel Jackson, Global Head of Market Access Policy, UCB
Mar 2311:25
Conference pass

Latest policy developments for medical devices in Italy

Market Access & Pricing: Medical Devices & Diagnostics
Marco Marchetti, Director Of The National Center For Health Technology Assessment, Istituto Superiore di Sanita
Mar 2311:25
Conference pass

Long-term profitable sustainability vs short-term profit maximization

Rare Diseases: Sustainability Of Orphan Drugs
Michael Schroter, Co-Head Sustainable Healthcare Equity, HSBC
Mar 2311:25
Conference pass

The gene therapy landscape in Germany: Future HTA and market considerations

Advanced Therapies: Risk-sharing, Access and Reimbursement
Axel Boehnke, Director Market Access EU North, PTC Therapeutics
Mar 2312:05
Conference pass

Developing the right skillset to support capability building

Evidence: Capability-building
Mitchell Payne, Global Head, Value and Access Excellence, Novartis Oncology
Mar 2312:05
Conference pass

Facilitating more efficient negotiations for innovative therapies: Value-based negotiation framework

Rare Diseases: Sustainability Of Orphan Drugs
Julien Patris, Director Market Access & Policy – Europe / Canada / MEA (CEMEA), Alnylam
Mar 2312:05
Conference pass

Examining hospital exemption for tissue engineering ATMP

Advanced Therapies: Risk-sharing, Access and Reimbursement
Andre Roeder, Head Global Market Access, TETEC AG
Mar 2312:25
Conference pass

Market access for companion diagnostics: Challenges & opportunities

Market Access & Pricing: Medical Devices & Diagnostics
Laura O'Hanlon, Director, Hereditary Cancer - International, Myriad genetics
Mar 2313:55
Conference pass

Roundtables

Keynotes
Roundtable 10: Exploring the challenges of demonstrating value for one-off treatments
Marika Russo, Market Access Director, Region Europe, NOVARTIS
Roundtable 11: Considerations for access planning for novel allogeneic cell therapies
Lung-I Cheng, Head of Global Value & Access, Cell Therapies, Oncology Business Unit, Takeda
Roundtable 12: Exploring the latest developments for market access and pricing in Italy
Lara Pippo, Head Of Market Access, Italy, CSL Behring
Roundtable 13: The importance of early engagement with payers prior to regulatory approval: Speeding up access to rare disease treatments
Suzanne Morgan, Director, Patient Access Services and National Accounts, NS Pharma, Inc.
Roundtable 14: Developing a multi-stakeholder engagement model that supports competitiveness for pharma
Mike Crosher, Managing Director, Chugai Pharma UK
Roundtable 15: Telemedicine and the Digital Momentum: Applying Key Learnings from the Impact of COVID 19 in the RWE Capability Evolution
Angelina Irizari Policarpio, Head of U.S. HEOR and RWE Communications Team (Market Access), Eisai
Roundtable 16: Access and pricing for companion diagnostics
Benjamin Gannon, Head of Int’l Access & Policy, Guardant Health
Roundtable 17: Pricing and payment for combination therapies
Lotte Steuten, Vice President And Head Of Consulting, Office of Health Economics
Roundtable 18: Exploring the role of pricing for mature products: From IRP to out of pocket costs
Margarida Costa, Global Pricing & Market Access Manager, Galderma
Roundtable 19: Multi-lateral advocacy approaches for shaping ATMP policy within Europe
Matt Slabbert, Global Lead – Public Affairs, Cell & Gene Therapy, Bayer
Roundtable 1: The role of cyber security in healthcare
Robert Orzechowski, Chief Operating Officer, Lancaster Cancer Centre
Roundtable 20: Pricing models for cell and gene therapies: What have we learned?
Paolo Morgese, EU Director Market Access & Member Relations, Alliance for Regenerative Medicine
Anna Bucsics, Project Advisor, Mechanism of Coordinated Access to orphan medicinal products (MoCA)
Roundtable 21: Enhance RWE developments to support rare diseases therapies commercialization and access
Phillip Hivale, Head of US Market Access and Value Communications, Healthcare Consultancy Group
Roundtable 22: Exploring the sustainability of orphan drugs
Mihaela Veringa, Senior Manager Global Access Policy & Govt. Affairs, Sobi
Roundtable 2: Pursuing a patient-centric approach to accelerating access to rare disease treatments
Melissa Paige, Associate Director, Payer/Market Access Marketing, NS Pharma, Inc.
Elizabeth Johnson, Co-founder, National Association of Medication Access & Patient Advocacy
Roundtable 3: Adopting a more patient-centred approach in pharma development: Does this speed up access for patients?
Jennifer Cain Birkmose, Vice President, Global Head Of Patient Access And Community Engagement, Swedish Orphan Biovitrum
Roundtable 4: Repurposed medicines: Key considerations for improving patient access
Catarina Lopes Pereira, Global Market Access Manager, Medac
Roundtable 5: How to use value-based contracting to improve patient access & care
Birgit Holz, Global Head of Contracting Innovation, Sanofi
Roundtable 6: Considerations for pricing & access strategies for biologics
Sandrine Ruiz, Global Pricing & Market Access Director, AstraZeneca
Roundtable 7: How to successfully negotiate a managed entry agreement: The dos and don’ts of contracting
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Roundtable 8: Valued-based frameworks: How do we capture value outside traditional parameters
Gwilym Thompson, Group Director Worldwide Health Economics and Outcomes Research, Markets (ROW), BMS
Roundtable 9: Considerations for market access and pricing in Spain
Jonathan Galduf, Director Market Access and Public Affairs (Iberia), CSL Behring
Carme Pinyol, Head Of Pricing And Market Access Southern Europe, Pierre Fabre
Mar 2314:50
Conference pass

Chair’s remarks

Evidence: Strategic Insight
Madhusudan Kabra, Director, Evidence Generation, Otsuka Pharmaceutical
Mar 2314:50
Conference pass

Chair’s remarks

Market Access & Pricing: Affordability
Natasa Zibelnik, Global Head of Value, Access and Pricing, Eusa Pharma
Mar 2314:50
Conference pass

Chair’s remarks

Rare Diseases: Accelerating Access To Treatments For Rare Diseases
Lisette Kaskens, Senior Global Market Access Manager, Advanced Accelerator Applications
Mar 2314:50
Conference pass

Chair’s remarks

Advanced Therapies: Risk-sharing, Access and Reimbursement
Gina Ewy, Head of Global Market Access, Hansa Biopharma
Mar 2314:55
Conference pass

Informing regulatory agencies, HTAs and payers using the totality of evidence from RWD, clinical trials & clinical expertise

Evidence: Strategic Insight
Mario Ouwens, Group Director Medical & Payer Evidence Statistics, AstraZeneca
Mar 2314:55
Conference pass

Economic & political considerations for affordability

Market Access & Pricing: Affordability
Joerg Mahlich, Market Access and Government Affairs Lead, Miltenyi Biomedicine GmbH
Mar 2314:55
Conference pass

Improving access to orphan drugs across Spain: National and regional developments

Rare Diseases: Accelerating Access To Treatments For Rare Diseases
José Luis Sánchez Chorro, Associate Director Market Access Spain, GW Pharmaceuticals
Mar 2314:55
Conference pass

Cross-border healthcare in Europe for cell & gene therapies

Advanced Therapies: Risk-sharing, Access and Reimbursement
Luigi Angelillo, Associate Director, HEOR & New Products Market Access (EMEA), Santen GmbH
Mar 2315:35
Conference pass

Considerations for developing an effective evidence generation strategy

Evidence: Strategic Insight
Valeriia Sokolova, Health Economics Manager, BIOCAD
Mar 2315:35
Conference pass

How do we ensure generics remain affordable and available

Market Access & Pricing: Affordability
Diogo Piedade, Market Access Manager, Medicines for Europe
Mar 2315:35
Conference pass

Overcoming early access hurdles for repurposed medicines in ultra-orphan indications

Rare Diseases: Accelerating Access To Treatments For Rare Diseases
Jelle Kleijn, Global Head of Acanthamoeba Keratitis, SIFI
Mar 2315:35
Conference pass

Increasing access to specialised treatment centres to improve outcomes for rare disease patients

Advanced Therapies: Risk-sharing, Access and Reimbursement
Thomas Bols, Head of Government Affairs and Public Policy, EMEA & APAC, PTC Therapeutics
Mar 2316:25
Conference pass

Chair’s remarks

Evidence: Strategic Insight
Elena Panitti, Global Head Real World Evidence Excellence, Novartis
Mar 2316:25
Conference pass

Chair’s remarks

Market Access & Pricing: Managed Entry Agreements
Birgit Holz, Global Head of Contracting Innovation, Sanofi
Mar 2316:25
Conference pass

Chair’s remarks

Rare Diseases: Accelerating Access To Treatments For Rare Diseases
Jennifer Cain Birkmose, Vice President, Global Head Of Patient Access And Community Engagement, Swedish Orphan Biovitrum
Mar 2316:25
Conference pass

Chair’s remarks

Advanced Therapies: Patient Centricity In Cell And Gene Therapies
Juan Roman, Vice President, Global Market Access, HEOR and Pricing, Krystal Biotech
Mar 2316:30
Conference pass

The real benefits of using an integrated evidence approach

Evidence: Strategic Insight
Melvin Olson, Global Head IE Strategy and Innovation, NOVARTIS
Mar 2316:30
Conference pass

Implementing managed entry agreements in Catalunya

Market Access & Pricing: Managed Entry Agreements
Laura Guarga, Consultant of Pharmacoeconomic Department, CatSalut
Mar 2316:30
Conference pass

Harnessing opportunities for safe, timely and patient centric innovation

Rare Diseases: Accelerating Access To Treatments For Rare Diseases
Maja Sercic, Policy & Science Manager, Medicines for Europe
Mar 2316:30
Conference pass

Achieving meaningful early engagement to shape your cell & gene therapy program

Advanced Therapies: Patient Centricity In Cell And Gene Therapies
Sarah Creviston, Vice President, Global Patient Advocacy & Government Affairs, Novartis Gene Therapies
Mar 2316:50
Conference pass

Removing barriers to patient access for rare disease medicines

Rare Diseases: Accelerating Access To Treatments For Rare Diseases
Thomas Hasmann, Vice President, Head of Market Access, Kyowa Kirin International
Mar 2317:10
Conference pass

Evidence strategies to support digital health

Evidence: Strategic Insight
Ali Ciger, Commercial Director, Pain, Pfizer
Mar 2317:10
Conference pass

Exploring innovation in managed entry agreements: From volume to usage of data

Market Access & Pricing: Managed Entry Agreements
Gomathi Kaliappan, Health Systems Strategy Leader - Global Access, Roche
Mar 2317:10
Conference pass

Ensuring the patient is at the forefront while navigating the orphan drug environment

Rare Diseases: Accelerating Access To Treatments For Rare Diseases
Suzanne Morgan, Director, Patient Access Services and National Accounts, NS Pharma, Inc.
Melissa Paige, Associate Director, Payer/Market Access Marketing, NS Pharma, Inc.
Mar 2317:10
Conference pass

Five years of launching advanced therapies in Germany: What are the lessons learned

Advanced Therapies: Patient Centricity In Cell And Gene Therapies
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)

Create your personal agenda –check the favourite icon

Mar 2409:55
Conference pass

Chair’s remarks

Keynotes
Declan Noone, President, European Haemophilia Consortium
Mar 2410:00
Conference pass

Insight from the Netherlands on the pilot parallel procedure: Accelerating access for patients

Keynotes
Ly Tran, Deputy Secretary, Scientific Advisory Council (Medicines Committee), Zorginstituut
Mar 2411:20
Conference pass

Chair’s remarks

Evidence: Patient And Clinical Outcomes
Josep Maria Guiu Segura, Head of Pharmacy, Pharmacy and Medicines Area, Consorci De Salut I Social De Catalunya
Mar 2411:20
Conference pass

Chair’s remarks

Market Access & Pricing: HTA
Alric Ruether, Head, International Affairs, IQWiG
Mar 2411:20
Conference pass

Chair’s remarks

Rare Diseases: Patient Advocacy
Mary Lynne Van Poelgeest-Pomfret, President, President of the World Federation for Incontinence and Pelvic Pain - WFIP
Mar 2411:20
Conference pass

Chair’s remarks

Emerging Markets: Middle East & Far East
Sam Taylor, Emerging Markets Strategic Pricing Lead, Pfizer
Mar 2411:25
Conference pass

Healthcare disparities in the developed world: Improving outcomes for patients across society

Evidence: Patient And Clinical Outcomes
John Alter, VP, Patient and Health Impact Lead, Hospital Business Unit, Pfizer
Mar 2411:25
Conference pass

Putting the patient at the heart of HTA

Market Access & Pricing: HTA
Josie Godfrey, Co-Founder and CEO, Realise Advocacy
Mar 2411:25
Conference pass

The benefit of a strong patient voice to ensure fair access

Rare Diseases: Patient Advocacy
Diane Langenbacher, Partner, Kautz5 gUG
Mar 2411:25
Conference pass

Is HTA fit for purpose in South East Asia?

Emerging Markets: Middle East & Far East
Alison Keetley, Head of Market Access South East Asia, Johnson & Johnson
Mar 2411:45
Conference pass

The evolution of HTA: Cost-effectiveness thresholds and benefit-assessments

Market Access & Pricing: HTA
Gavin Lewis, Global Head of Market Access, Amgen
Mar 2412:05
Conference pass

Harnessing RWD to improve patient outcomes

Evidence: Patient And Clinical Outcomes
Igor Rudychev, Vice President, Enterprise Analytics, Horizon Therapeutics
Mar 2412:05
Conference pass

The evolving landscape for HTA in Switzerland

Market Access & Pricing: HTA
Goedele Van Haasteren, Staff Member, Swiss Federal Office of Public Health
Mar 2412:05
Conference pass

Behind the buzz of patient advocacy: Delivering actionable results for patients

Rare Diseases: Patient Advocacy
Elizabeth Johnson, Co-founder, National Association of Medication Access & Patient Advocacy
Mar 2412:05
Conference pass

The development of pricing mechanisms & policies in the Middle East and North Africa

Emerging Markets: Middle East & Far East
Ayman Semaan, Head of Market Access, Biologix
Mar 2412:25
Conference pass

Latest update on the EU HTA system

Market Access & Pricing: HTA
Marcus Guardian, Chief Operating Officer, EUnetHTA
Mar 2412:25
Conference pass

Access and pricing in Israel

Emerging Markets: Middle East & Far East
Tomer Ben Zaken, Pricing And Alliance Manager, Takeda
Mar 2413:55
Conference pass

Roundtables

Keynotes
Roundtable 10: Developing novel approaches for fostering innovation and patient access
Anne Willemsen, Senior Project Manager, Zorginstituut Nederland / EUnetHTA
Diogo Teixeira Pereira, Policy Analyst - Office for International Relations and Development, Infarmed
Roundtable 11: The value of the safety profile for innovative products
Jost Leemhuis, Head Of Safety Science, Roche
Roundtable 12: Down to the cents: Examining international drug pricing
Bill Hu, Professor of Finance, Arkansas State University
Roundtable 13: Expanding access in LMICs through affordable pricing strategies
Diane Munch, Head of Global Pricing, Patient & Health Impact, Pfizer
Roundtable 14: The impact of pivotal study designs on patient access
Sigrid Klaar, Medical advisor, The Dental and Pharmaceutical Benefits Agency T.L.V.
Roundtable 15: Emerging markets: Planning and executing RWE for policy shaping & expanding access
Vijay Reddy, Senior Director - Global Market Access Strategy - Biologics, Biocon Biologics
Roundtable 1: Examining the acceptability of pragmatic trials
Helene Chevrou-Severac, HEOR RWE Centre of Excellence Head, International & Japan, Alexion
Roundtable 2: Examining the latest access and pricing developments in Latin America
Marcelo Sal, Head of Market Access and Pricing, South Cone of South America, PTC Therapeutics
Diego Guarin, Executive Director, Regional Market Access Latin America, Global Market Access, Merck
Marcela Junqueira, Oncology Market Access Director - Latin America, Janssen Pharmaceutical
Roundtable 3: Considerations on the creation of a EU HTA system
Thomas Mueller, Head Of Directorate General 1 - Drugs, Medical Devices, Biotechnology, Federal Ministry of Health Germany
Marcus Guardian, Chief Operating Officer, EUnetHTA
Roundtable 4: What can be done to improve collaboration between patients and pharma?
Dawn Ireland, President, CDH International
Roundtable 5: Opportunities and challenges in Asia-Pacific/Chinese healthcare system: What to watch out for?
Kris Thiruvillakkat, Sr Director, Global Evidence Market Access Pricing, CSL Behring
Roundtable 6: Examining the latest access and pricing developments in the Middle East
Rita Shorjian, Business Unit Director – Gulf Countries, Specialty, HCV & Oncology, Abbvie
Roundtable 7: Shared experiences on G-BA required registries for orphan drugs
Friedhelm Leverkus, Director Health Technology Assessment And Outcomes Research, Pfizer
Roundtable 8: What role does the quality of life have in payer decision-making?
Monika Szkultecka-Debek, Vice President, Qualitas Vitae Institute Foundation
Roundtable 9: Exploring the affordability of medicines in a post-pandemic world
David Watson, Executive Director, Economic, Health and Commercial Policy, ABPI
Mar 2414:55
Conference pass

Chair’s remarks

Evidence: Patient And Clinical Outcomes
Gilles Ducorroy, Global Head of RWE Services, Novartis
Mar 2414:55
Conference pass

Chair’s remarks

Market Access & Pricing: HTA
Carme Pinyol, Head Of Pricing And Market Access Southern Europe, Pierre Fabre
Mar 2414:55
Conference pass

Chair’s remarks

Rare Diseases: Patient Advocacy
Sheela Upadhyaya, Accelerated Access Collaborative Relationship & Delivery Lead & HST Specialist, National Institute for Health and Care Excellence
Mar 2414:55
Conference pass

Chair’s remarks

Emerging Markets: Latin America
Ana Plata, Global Head of Pricing, UCB
Mar 2415:00
Conference pass

Effectively integrating evidence relevant to payers in pivotal studies

Evidence: Patient And Clinical Outcomes
Michael Ermisch, Specialist, Department Of Pharmaceuticals, G.K.V. Spitzenverband
Mar 2415:00
Conference pass

New approaches to the assessment of orphan drugs in Russia

Market Access & Pricing: HTA
Nuriya Musina, Head Of Development, Federal State Budgetary Institution, The Center For Healthcare Quality Assessme, Ministry of Health Russian Federation
Mar 2415:00
Conference pass

How to get going and keep going: Leveraging resources effectively to support your advocacy campaign

Rare Diseases: Patient Advocacy
Edmund Lim, Executive Director, We CARE Journey
Mar 2415:00
Conference pass

The impact of the Pandemic on the regulatory landscape of Latin America

Emerging Markets: Latin America
Maria Alejandra Blanc, Director - Regulatory Affairs – Region South, Abbvie
Mar 2415:20
Conference pass

How do we integrate G-BA requirements into clinical trials: Recognizing the key end points and limitations

Evidence: Patient And Clinical Outcomes
Friedhelm Leverkus, Director Health Technology Assessment And Outcomes Research, Pfizer
Mar 2415:20
Conference pass

Perspectives from Poland on the development of European HTA legislation

Market Access & Pricing: HTA
Dominik Dziurda, Head Of Health Services Division, AOTMiT
Mar 2415:20
Conference pass

The fair market value of patient advocacy in the US: A real world model

Rare Diseases: Patient Advocacy
Nadia Bodkin, OLM DEI Expert, Rare Advocacy Movement
Mar 2415:20
Conference pass

Pricing and market access for disruptive medicines in Brazil

Emerging Markets: Latin America
Jonas Sertorio, Innovation and HTA Consultant, Ministry of Health - Brazil
Mar 2415:40
Conference pass

How COVID-19 has impacted clinical outcomes for Dupilumab

Evidence: Patient And Clinical Outcomes
Ajinkya Pawar, Director, Real World Investigator, Dupilumab | Respiratory, Sanofi
Mar 2415:40
Conference pass

How pharma can inform patients, advocates & carers in using the HTAi summary of information for patients (SIP)

Market Access & Pricing: HTA
Clare Hague, Therapy Area Market Access Lead, Hematology, Janssen Pharmaceuticals
Mar 2415:40
Conference pass

Moving beyond traditional advocacy: Applying a systems change vision

Rare Diseases: Patient Advocacy
Amanda Bok, CEO, European Haemophilia Consortium
Mar 2415:40
Conference pass

The impact of pricing components in access to medicines for Latam

Emerging Markets: Latin America
Giovanny Leon, Pricing & Access Regional Director - LatAm & Canada, Novartis AG
Mar 2416:00
Conference pass

Evidence generation in the setting of severely ill patients: Practical experiences in early & late-stage clinical development

Evidence: Patient And Clinical Outcomes
Erik Van Den Berg, Chief Executive Officer, A.M. Pharma
Mar 2416:00
Conference pass

Transforming the financing of the Saudi healthcare system

Market Access & Pricing: HTA
Abdulrahman AlMesnid, Health Economic Evaluation Lead, Ministry of Health
Mar 2416:00
Conference pass

Stakeholder involvement and deliberative processes to support coverage decisions of new technologies in Latin America

Emerging Markets: Latin America
Andres Pichon Riviere, Executive Director And Director Of Health Technology Assessment And Economic Evaluations, I.E.C.S.
last published: 14/Sep/21 15:55 GMT
 

Get Involved 
 

Connect  

 

 

To Sponsor Or Exhibit


David Boore 
david.boore@terrapinn.com   
+44 20 7092 1047

To Speak


Chris Shanks
Chris.Shanks@terrapinn.com  
+44 20 7092 1070